RecruitingNCT06654895
Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study
Sponsor
Bluejay Diagnostics, Inc.
Enrollment
700 participants
Start Date
Nov 12, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The primary objective of this study is to validate a pre-defined IL-6 concentration cutoff that predicts 28-day mortality in patients who are admitted or are intended to be admitted to the ICU diagnosed with sepsis or septic shock.
Eligibility
Min Age: 22 Years
Plain Language Summary
Simplified for easier understanding
This study is testing whether a bedside device that continuously monitors IL-6 — a protein that spikes when the body is fighting a serious infection — can help doctors better track and manage sepsis (a life-threatening infection response) and septic shock in ICU patients.
**You may be eligible if...**
- You are 22 or older
- You are an ICU patient who meets the clinical criteria for sepsis or septic shock (suspected or confirmed infection causing organ dysfunction, or requiring medications to maintain blood pressure)
**You may NOT be eligible if...**
- You are under 22 years old
- You do not meet the diagnostic criteria for sepsis or septic shock
- You are unable to provide consent (or a surrogate cannot)
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06654895